Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection

Core Evidence

Volumn 4, Issue , 2009, Pages 149-158

  Stellbrink, Hans Jürgen ^a  

^a Infektionsmedizinisches Centrum Hamburg   (Germany)

Author keywords

Etravirine; Evidence; HIV 1

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; RALTEGRAVIR; RITONAVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG COST; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERSENSITIVITY REACTION; MENTAL DISEASE; NAUSEA; RASH; REVIEW; SALVAGE THERAPY; STEVENS JOHNSON SYNDROME; TREATMENT FAILURE; VIRUS STRAIN;

EID: 79955104095     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Anon. INTELENCE™ (etravirine) Tablets. Raritan NJ: Tibotec Therapeutics, Division of Ortho Biotech Products L.P. 2008.
2. UNAIDS (the Joint United Nations Programme on HIV/AIDS). AIDS epidemic update: December 2007. Available at: http://www.google. co.uk/search?hl= en&q=UNAIDS.+AIDS+epidemic+update+%3A+December+2007&btnG= Search&meta=
3. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860. (Pubitemid 28135961)
4. Losina E, Yazdanpanah Y, Duffic-Burban S, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Cote d'Ivoire. Antivir Ther. 2007:12;543-551. (Pubitemid 47041153)
5. Bezemer D, Jurriaans S, Prins M, et al. Declining trend in transmission of drug-resistant HIV-1 in Amsterdam. Aids. 2004;18:1571-1577. (Pubitemid 39037481)
6. Yerly S, von WV, Ledergerber B, et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. Aids. 2007;21:2223-2229. (Pubitemid 350287221)
7. SP (SPREAD Programme). Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008;22:625-630.
8. Vercauteren J, Deforche K, Theys K, et al. The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology. 2008;5:12.
9. Masquelier B, Bhaskaran K, Pillay D, et al. Prevalence of transmitted HIV-1 drug resistance and the role of resistance algorithms: data from seroconverters in the CASCADE collaboration from 1987 to 2003. J Acquir Immune Defic Syndr. 2005;40:505-511.
10. Chaix ML, Desquilbet L, Descamps D, et al. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network. Antivir Ther. 2007;12:1305-1310.
11. Poggensee G, Kucherer C, Werning J, et al. Impact of transmission of drug-resistant HIV on the course of infection and the treatment success. Data from the German HIV-1 Seroconverter Study. HIV Med. 2007;8:511-519.
12. Riddler SA, Haubrich R, DiRienzo G, et al; for the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-2106. (Pubitemid 351679596)
13. Clotet B. Efavirenz: resistance and cross-resistance. Int J Clin Pract Suppl. 1999;103:21-25. (Pubitemid 29341325)
14. Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol. 2001;65:445-458.
15. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347. (Pubitemid 40139758)
16. Koval CE, Dykes C, Wang J, Demeter LM. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. Virology. 2006;353:184-192. (Pubitemid 44291782)
17. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol. 1997;71:1089-1096. (Pubitemid 27030280)
18. Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol. 1998;72:3773-3778. (Pubitemid 28188675)
19. Picchio GR, Valdez H, Sabbe R, et al. Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy. J Acquir Immune Defic Syndr. 2000;25:289-295. (Pubitemid 32107160)
20. Prado JG, Franco S, Matamoros T, et al. Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215. Virology. 2004;326:103-112. (Pubitemid 38943010)
21. Wainberg MA. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther. 2004;2:147-151. (Pubitemid 38735755)
22. Loubser S, Balfe P, Sherman G, et al. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. Aids. 2006;20:995-1002.
23. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005;192:24-29. (Pubitemid 40863853)
24. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr. 2006;42:610-613. (Pubitemid 44162432)
25. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis. 2007;195:711-715.
26. Hardy D, Reynes J, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-tropic HIV-1: 48-week combined analysis of the MOTIVATE studies. 15th Con Retrovir Opportun Infect, Boston. 2008. Abstract 792.
27. Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis. 2007;44:591-595. (Pubitemid 46233265)
28. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis. 2005;192:466-474. (Pubitemid 41023125)
29. Saag M, Prudence I, Heera J, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV-1: Week 48 results of the MERIT study. 4th IAS Conference Sydney, Australia. 2007. Abstract WESS104.
30. Westby M, Lewis M, Whitcomb, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006;80:4909-4920.
31. Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(Suppl 1):38-46. (Pubitemid 351366537)
32. Cooper DA, Gatell J, Rockstroh J, et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conf Retro Opportun Infect Los Angeles. 2007. Abstract 105aLB.
33. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261-1269. (Pubitemid 46553846)
34. Steigbigel R, Kumar P, Eron J, et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conf Retro Opportun Infect Los Angeles, CA. 2007. Abstract 105bLB.
35. Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35:1657-1663. (Pubitemid 47296061)
36. Anon. ISENTRESS™ Tablets (package insert). Whitehouse Station NJ: Merck & Co, 2007.
37. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:4680-4686. (Pubitemid 39577672)
38. Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem. 2004;47:2550-2560. (Pubitemid 38580092)
39. Vingerhoets J, Azijn H, Fransen E, et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005;79:12773-12782. (Pubitemid 41433197)
40. Gruzdev B, Rakhmanova A, Doubovskaya E, et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS. 2003;17:2487-2494. (Pubitemid 38393321)
41. Gazzard BG, Pozniak AL, Rosenbaum W, et al. An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. Aids. 2003;17:F49-F54. (Pubitemid 38402332)
42. Woodfall B, Vingerhoets J, Peeters M, et al. Impact of NNRTI and NRTI resistance on the response to the regimen of TMC125 plus two NRTIs in study TMC125-C227. International Congress on Drug Therapy in HIV Infection. Glasgow, UK. 2006a. Abstract PL5.6.
43. Montaner J, Yeni P, Clumeck NN, et al. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis. 2008;47:969-978.
44. Nadler JP, Berger DS, Blick G, et al. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. Aids. 2007;21:F1-F10. (Pubitemid 46568620)
45. Kakuda TN, Scholler-Gyure M, Workman C, et al. Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1 -infected patients. Antivir Ther. 2008a;13:655-661.
46. Woodfall B, De Smedt G, Berckmans C, Baeten B, Peeters M. No frequent reporting of neurological or psychiatric events during TMC125 treatment. 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK. 2006b. Abstract 146.
47. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48. (Pubitemid 47017467)
48. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38. (Pubitemid 47017466)
49. Di Biagio A, Bruzzone B, Rosso R, et al. Successful rescue therapy with raltegravir (MK-0518) and etravirine (TMC125) in an HIV-infected patient failing all four classes of antiretroviral drugs. AIDS Patient Care STDS. 2008;22:355-357. (Pubitemid 351735877)
50. Poveda E, Garrido C, de Mendoza C, et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 2007;60:1409-1410. (Pubitemid 350168348)
51. Lapadula G, Calabresi A, Castelnuovo F, et al. Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. Antivir Ther. 2008a;13:601-605. (Pubitemid 352016723)
52. Llibre JM, Santos JR, Puig T, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother. 2008;62:909-913.
53. Lapadula G, Izzo I, Gargiulo F. Updated prevalence of genotypic resistance among HIV-1 positive patients naive to antiretroviral therapy: a single center analysis. J Med Virol. 2008b;80:747-753. (Pubitemid 351500018)
54. Molina JM, Cordoba J, Gil A, Gobernado M. Epidemiology of genotypic resistance of HIV-1 in Valencia. A 4-year study. Rev Esp Quimioter. 2007;20:346-353.
55. Di Vincenzo P, Rusconi S, Adorni F, et al. Prevalence of mutations and determinants of genotypic resistance to Etravirine (TMC125) in a large Italian resistance database (ARCA). 6th European HIV Drug Resistance Workshop, Budapest, Hungary. 2008. Abstract 59.
56. Vingerhoets J, Clotet B, Peeters M, et al. Impact of baseline NNRTI mutations on the virological response to TMC125 (etravirine; ETR) in the DUET-1 and DUET-2 Phase III clinical trials. 11th EACS European AIDS Conference, Madrid, Spain. 2007. Abstract P7.3/05.
57. Kakuda TN, Scholler-Gyure M, Woodfall BJ, et al. TMC125 in combination with other medications: summary of drug-drug interactions. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland. 2006. Abstract PL5.6. 2006.
58. Schöller-Gyüre M, Kakuda TN, de Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-volunteers. Br J Clin Pharmacol. 2008a;66:508-516.
59. Peeters M, Janssen K, Kakuda TN, et al. Etravirine has no effect on QT and corrected QT interval in HIV-negative volunteers. Ann Pharmacother. 2008;42:757-765. (Pubitemid 351778082)
60. Beck EJ, Mandalia S, Youle M, et al. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002). Int J STD AIDS. 2008;19:297-304.
61. Ruof J, Dusek A, DeSpirito M, Demasi RA. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients. Clin Drug Investig. 2007;27:469-479. (Pubitemid 46919699)
62. Lampe FC, Gatell JM, Staszewski S, et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multi-cohort analysis, 1996 to 2002. Arch Intern Med. 2006;166:521-528.
63. Lohse N, Obel N, Kronborg G, et al. Declining risk of triple-class antiretroviral drug failure in Danish HIV-infected individuals. Aids. 2005;19:815-822. (Pubitemid 40834752)
64. Di Giambenedetto S, Bracciale L, Colafigli M, et al. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Antivir Ther. 2007;12:835-839. (Pubitemid 47235499)
65. Phillips AN, Leen C, Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet. 2007;370:1923-1928. (Pubitemid 350193334)
66. Napravnik S, Keys JR, Quinlivan EB, Wohl DA, Mikeal OV, Eron JJ Jr. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients. Aids. 2007;21:825-834. (Pubitemid 46573154)
67. Davis J, Scholler-Gyure M, Kakuda TN, et al. An open, randomized, two-period, crossover study in two cohorts to investigate the effect of steady-state TMC125 (etravirine) and the combination of TMC125/darunavir/ ritonavir on the steady-state Pharmacokinetics of Oral Maraviroc in Healthy Subjects. 11th European AIDS Conference/EACSMadrid, Spain. 2007. Abstract P4.3/02.
68. Schöller M, Kraft M, Hoetelmans R, et al. Significant decrease in TMC125 exposures when co-administered with tipranavir (boosted with ritonavir) in healthy subjects. 13th Conference on Retroviruses and Opportunistic Infections (CROI), Denver, CO. 2006. Abstract 583.
69. Schöller-Gyüre M, Woodfall B, Bollen S, Peeters M, Vandermeulen K, Hoetelmans, R. Pharmacokinetics of amprenavir and TMC125 in HIV-infected volunteers receiving TMC125with fosamprenavir/ritonavir. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2006a. San Francisco, CA. Abstract A-370.
70. Schöller-Gyüre M, Woodfall B, De Marez T, et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir. 8th International Congress on Drug Therapy in HIV infection, Glasgow, UK. 2006b. Abstract P278.
71. Piscitelli SC, Baede P, Van't Klooster G, Graham N. TMC125 does not alter lopinavir/ritonavir (LPV/RTV) pharmacokinetics in healthy volunteers. 42nd Intersci Conf Antimicrob Agents Chemother San Diego, CA. 2002. Abstract A-1824.
72. Schöller-Gyüre M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 2007;12:789-796. (Pubitemid 47235493)
73. Schöller-Gyüre M, van den BW, Kakuda TN, et al. Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. J Clin Pharmacol. 2008b;48:322-329. (Pubitemid 351257768)
74. PE (Panel of Experts). Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. European AIDS Clinical Society (EACS). 2007. Available at: http://www.eacs.eu/guide/index.htm.
75. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med. 2008;9:65-71. (Pubitemid 351228129)
76. PAGAA (Panel on Antiretroviral Guidelines for Adults and Adolescents). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2008. Available at: http://www.aidsinfo. nih. gov/Guidelines/GuidelineDetail.aspx?MenuItem= Guidelines&GuidelineID=7.
77. Kakuda T, Konigs C, Feiterna-Sperling C, et al. Pharmacokinetics of the next-generation NNRTI TMC125 in HIV-infected children between 6 and 17 years of age. 15th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA. 2008b. Abstract 578.